BAMF
ICPT

BI Asset Management Fondsmaeglerselskab’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

BI Asset Management Fondsmaeglerselskab’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-552
Closed -$44K – 381
2019
Q2 		$44K Buy
+552
New +$49.4K ﹤0.01% 239

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BI Asset Management Fondsmaeglerselskab's ICPT Position: Q3 2019 in Review

BI Asset Management Fondsmaeglerselskab sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q3 2019, closing a stake of 552 shares — an estimated $44K sold.

BI Asset Management Fondsmaeglerselskab first reported a position in ICPT in Q2 2019 and held it in 1 quarter. The position peaked at $44K in Q2 2019. 188 funds tracked by Wall St. Rank hold ICPT as of Q3 2019.

  • BI Asset Management Fondsmaeglerselskab reported no remaining Intercept Pharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
  • BI Asset Management Fondsmaeglerselskab sold 552 Intercept Pharmaceuticals, Inc. shares in Q3 2019, an estimated $44K.
  • BI Asset Management Fondsmaeglerselskab first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2019 and held it in 1 quarter.
  • BI Asset Management Fondsmaeglerselskab's Intercept Pharmaceuticals, Inc. position peaked at $44K in Q2 2019.
  • 188 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q3 2019.

Based on BI Asset Management Fondsmaeglerselskab's 13F filing for Q3 2019, filed 19 Mar 2020.